MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR,respectively

MicroRNAs have been identified as key players in the development and progression of osteosarcoma, which is the most common primary malignancy of bone. Sequencing-based miR-omic and quantitative real-time PCR analyses suggested that the expression of miR-193a-3p and miR-193a-5p was decreased by DNA methylation at their promoter region in a highly metastatic osteosarcoma cell line (MG63.2) relative to their expression in the less metastatic MG63 cell line. Further wound-healing and invasion assays demonstrated that both miR-193a-3p and miR-193a-5p suppressed osteosarcoma cell migration and invasion. Moreover, introducing miR-193a-3p and miR-193a-5p mimics into MG63.2 cells or antagomiRs into MG63 cells confirmed their critical roles in osteosarcoma metastasis. Additionally, bioinformatics prediction along with biochemical assay results clearly suggested that the secretory small GTPase Rab27B and serine racemase (SRR) were direct targets of miR-193a-3p and miR-193a-5p, respectively. These two targets are indeed involved in the miR-193a-3p- and miR-193a-5p-induced suppression of osteosarcoma cell migration and invasion. MiR-193a-3p and miR-193a-5p play important roles in osteosarcoma metastasis through down-regulation of the Rab27B and SRR genes and therefore may serve as useful biomarkers for the diagnosis of osteosarcoma and as potential candidates for the treatment of metastatic osteosarcoma.     

miR-27a-3p靶向HOXA5基因通过Wnt/β-catenin信号通路调控糖尿病患者创面愈合

目的:研究微小RNA-27a-3p(miR-27a-3p)对糖尿病患者创面愈合的影响及作用机制。方法:采用qPCR和Western blot检测糖尿病患者创面愈合组织中miR-27a-3p、同源异型盒基因A5(HOXA5)mRNA和HOXA5蛋白的表达。使用高糖处理人微血管内皮细胞(HMECs),模拟糖尿病HMECs的损伤。在HMECs中转染miR-27a-3p mimic或HOXA5 siRNA,并进行高糖处理,MTT法测定细胞活力,Transwell小室法检测细胞迁移和侵袭能力,Western blot法测定HOXA5、细胞周期蛋白D1(cyclin D1)、基质金属蛋白酶2(MMP2)、基质金属蛋白酶9(MMP9)和β-连环蛋白(β-catenin)蛋白的表达。StarBase预测结合双萤光素酶活性检测分析miR-27a-3p和HOXA5的靶向关系。在HMECs中共转染miR-27a-3p mimic和pcDNA-HOXA5,并使用高糖处理,观察其对细胞活力、迁移和侵袭能力的影响。结果:糖尿病患者创面愈合组织中miR-27a-3p的表达量明显减少,HOXA5的mRNA和蛋白表达量显著增加(P<0.05)。高糖诱导的HMECs中miR-27a-3p的表达量、细胞活力、细胞迁移和侵袭数量及cyclin D1、MMP2和MMP9的蛋白水平均显著降低(P<0.05)。高表达miR-27a-3p或低表达HOXA5明显增加高糖处理HMECs的细胞活力、迁移和侵袭能力及cyclin D1、MMP2和MMP9的蛋白表达量(P<0.05)。miR-27a-3p靶向调控HOXA5表达。高表达HOXA5可以部分消除miR-27a-3p mimic对高糖处理的HMECs活力、迁移和侵袭能力以及cyclin D1、MMP2、MMP9和β-catenin蛋白表达的影响。结论:miR-27a-3p靶向HOXA5基因,并通过Wnt/β-catenin信号通路促进高糖诱导的微血管内皮细胞生长、迁移和侵袭,从而促进糖尿病患者的创面愈合。     

Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro

Chemoresistance is a major obstacle in treating cancer, including osteosarcoma. LncRNA ANRIL (ANRIL) is involved in the growth and metastasis of osteosarcoma cells, however, its role in chemoresistance remains unclear. In this study, ANRIL shRNA was used to knock down its endogenous expression in U2-OS and Saos-2 osteosarcoma cell lines. Our data showed that ANRIL-silenced cells were more sensitive to cisplatin: apoptotic ratio was increased and cleaved caspase-3 level was upregulated. Furthermore, the expression level of miR-125a-5p, a microRNA that can bind to ANRIL, was elevated in ANRIL-silenced cells. MiR-125a-5p inhibitor attenuated ANRIL knockdown-induced chemosensitivity to cisplatin. In addition, ANRIL knockdown resulted in a reduction in STAT3, a target of miR-125a-5p, in osteosarcoma cells. Forced overexpression of STAT3 weakened the chemosensitivity of ANRIL-silenced cells to cisplatin. In conclusion, our study demonstrates that ANRIL knockdown sensitizes osteosarcoma cells to cisplatin-induced cytotoxicity, suggesting ANRIL as a therapeutic target for osteosarcoma chemotherapy.     

MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether à go-go 1 Expression

Aberrant expression of MicroRNAs (miRNAs) has been implicated in several types of cancer. As a direct target gene of p53, miR-34a has been suggested to mediate the tumor suppressor function of p53. Ether à go-go 1 (Eag1) channel is overexpressed in a variety of cancers and plays important roles in cancer progression. However, the link between miR-34a and Eag1 in cancer is unclear. In this study, we used human osteosarcoma as the model to demonstrate that miR-34a was significantly downregulated in osteosarcoma tissues and cell lines compared with normal brain tissues and osteoblastic cell line. Next we evaluated the role of miR-34a in the regulation of osteosarcoma cell proliferation by CCK-8 and colony formation assays. The results showed that overexpression of miR-34a inhibited the proliferation of MG-63 and Saos-2 cells. Furthermore, xenograft nude mice model showed that miR-34a inhibited osteosarcoma growth in vivo. Mechanistically, we found that overexpression of miR-34a led to decreased Eag1 expression in osteosarcoma cells while inhibition of miR-34a increased Eag1 expression. Taken together, our results suggest that miR-34a could inhibit osteosarcoma growth via the down regulation of Eag1 expression.     

miR-199a-3p targets ETNK1 to promote invasion and migration in gastric cancer cells and is associated with poor prognosis

PurposeTo investigate the prognostic significance of miR-199a-3p and its role in invasion and metastasis in gastric cancer.MethodsmiR-199a-3p expression in 436 formalin-fixed and 39 frozen gastric cancer tissues was investigated by in situ hybridization and RT-PCR, respectively. The role of miR-199a-3p in the migration and invasion of gastric cancer cells was determined in overexpression and inhibitor studies using transwell assays and the SGC-7901, BGC-823 and MGC-803 gastric cancer cells lines. The effect of miR-199a-3p expression on ethanolamine kinase 1 (ETNK1) levels was determined by western botting.ResultsmiR-199a-3p was significantly up-regulated in AGS, SGC-7901, BGC-823 and MGC-803 gastric cancer cells, when compared with GES-1 non-malignant gastric epithelial cells. In situ hybridization studies revealed that human non-tumor gastric mucosa samples were negative for miR-199a-3p expression, while 162 of 436 (37.16%) cases of gastric cancer demonstrated positive expression. miR-199a-3p overexpression was associated with tumor size, Lauren classification, depth of invasion, lymph node and distant metastasis, TNM stage and prognosis. In patients with I, II and III stage tumors, high miR-199a-3p expression was associated with a significantly lower 5-year survival rate. miR-199a-3p overexpression was associated with increased cell migration and invasion. ETNK1 expression was inhibited following miR-199a-3p overexpression in BGC-823 and SGC-7901 cells, and elevated following miR-199a-3p suppression in MGC-803 cells.ConclusionmiR-199a-3p is highly expressed in gastric cancer, and correlates with invasion, metastasis and prognosis. miR-199a-3p regulates the invasion and migration of gastric cancer cells by targeting ETNK1. Consequently, miR-199a-3p may serve as a prognostic indicator in gastric cancer.     

Circular RNA circEGFR regulates tumor progression via the miR-106a-5p/DDX5 axis in colorectal cancer

Recently, an increasing number of studies have reported that dysregulation of circular RNA (circRNA) expression plays critical roles in the progression of several cancers, including colorectal cancer (CRC). However, the detailed molecular mechanisms of circRNAs involvement in CRC remain largely unknown. Here, we confirmed that the level of circEGFR was significantly increased in CRC tissues compared to matched adjacent non-tumor tissues, and a high level of circEGFR was correlated with poor clinicopathological characteristics and poor prognosis in patients with CRC. Moreover, increased circEGFR expression promoted CRC cell proliferation, migration, and invasion in vitro. Mechanistically, circEGFR acted as a ceRNA for miR-106a-5p to relieve the repressive effect of miR-106a-5p on DDX5 mRNA. Moreover, circEGFR enhanced DDX5 expression, thereby upregulating p-AKT levels. Together, these findings showed that circEGFR promoted CRC cell proliferation, migration, and invasion through the miR-106a-5p/DDX5/AKT axis, and may serve as a promising diagnostic marker and therapeutic target for CRC patients.     

MiRNA-15a inhibits proliferation,migration and invasion by targeting TNFAIP1 in human osteosarcoma cells

Recent data strongly suggest the important role of miRNAs in various cancer-related processes. Osteosarcoma is the most common type of primary malignant bone tumor and is characterized by complex genetic changes and resistance to conventional treatments. In this study, the role of miRNA-15a (miR-15a) in the progression and metastasis of osteosarcoma was investigated. The result demonstrated that the expression of miR-15a was down-regulated in osteosarcoma tissues and cell lines as compared with that in adjacent non-neoplastic bone tissues and the osteoblastic cell line. In functional assays, miR-15a inhibited cell proliferation, migration and invasion in U2OS and MG-63 cells. Meanwhile, bioinformatic analysis combined with experimental confirmation demonstrated that tumor necrosis factor; α-induced protein 1 (TNFAIP1) gene is a potential target of miR-15a and can be directly regulated by miR-15a. Down-regulation of TNFAIP1 induced effects on osteosarcoma cell lines similar to those induced by miR-15a. Taken together, these data suggest that miR-15a may act as a tumor suppressor, which is commonly down-regulated in both osteosarcoma tissues and cells. TNFAIP1 plays an important role in mediating miR-15a dependent biological functions in osteosarcoma. Reintroduction of miR-15a may be a novel therapeutic strategy by down-regulating TNFAIP1 expression.     

MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells

MicroRNAs (miRNAs) are endogenous, non-coding, small RNAs, which play a critical role in regulating varieties of the biological and pathologic processes. Several reports have indicated that miR-370 acts as a tumor suppressor in varieties of tumors. However, the roles of miR-370 in osteosarcoma have not been reported. In this study, our objective was to explore the biological functions and its molecular mechanism of miR-370 in osteosarcoma cell lines, finding a therapeutic target of osteosarcoma. Our data demonstrated that miR-370 was evidently reduced in osteosarcoma cell lines, whereas FOXM1 expression was markedly increased. Up-regulation of miR-370 suppressed proliferation, arrested cell cycle and induced apoptosis in osteosarcoma cells. Besides, invasion and EMT of osteosarcoma cells was also inhibited by introduction of miR-370. Next, we found that FOXM1 expression was significantly reduced by up-regulation of miR-370. Bioinformatics analysis predicted that the FOXM1 was a potential target gene of miR-370. Luciferase reporter assay further confirmed that miR-370 could directly target the 3’ UTR of FOXM1. Overexpression of FOXM1 in osteosarcoma cells transfected with miR-370 mimic partially reversed the effects of miR-370. In conclusion, miR-370 inhibited cell growth and metastasis in osteosarcoma cells by down-regulation of FOXM1.     

Profilin 1, negatively regulated by microRNA-19a-3p,serves as a tumor suppressor in human hepatocellular carcinoma

Profilin 1 (PFN1) is a critical actin-regulatory protein; however, its functional role in hepatocellular carcinoma (HCC) progression remains to be further elucidated. In the present study, we observed that the expression levels of PFN1 were significantly decreased in HCC tissues and cell lines. Low PFN1 expression was significantly correlated with aggressive clinicopathological characteristics and poor prognosis of HCC patients. Further in vitro experiments demonstrated that overexpression of PFN1 remarkably inhibited the proliferation, migration, invasion and EMT of HCC cells. Moreover, we also found that PFN1 was a direct target gene of miR-19a-3p, and in HCC tissues, and there was a significantly inverse correlation between PFN1 mRNA and miR-19a-3p expression. Collectively, our results showed that PFN1 functions as a tumor suppressor in HCC, and might serve as a diagnostic and therapeutic target for HCC patients.     

DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p

Ovarian cancer (OvCa) has the highest morbidity among all gynecologic cancers worldwide, and its distant metastasis is one of main causes for the poor prognosis of OvCa patients. Our previous studies have reported that DAAM1-involved signaling pathways play vital roles in metastasis of breast cancer. However, whether DAAM1 participates in OvCa migration and/or invasion is still unknown. The impact of DAAM1 on cell migration and invasion in OvCa was evaluated by wound healing assay and Boyden chamber assay. The specific miRNA targeting DAAM1 was predicted by bioinformatics methods and verified by dual-luciferase activity assay. The miR-208a-5p expression levels in OvCa tissues and the impacts of miR-208a-5p on cell migration and invasion were also assessed, respectively. High expression of DAAM1 was associated with distant metastasis in OvCa. Silence of DAAM1 by siRNA blocked the migration and invasion of OVCAR-3 cells. MiR-208a-5p directly targeted DAAM1 and was shown a decreased expression in metastatic OvCa tissues. Elevated expression of miR-208a-5p inhibited the migration and invasion of OVCAR-3 cell which can be rescued by DAAM1 overexpression. Our data suggest that miR-208-5p/DAAM1 axis participates in OvCa migration and invasion and may be a novel clinical target to limit OvCa metastasis.     

miR-130a-3p 通过调控 PDK1 影响肝癌细胞糖代谢的研究

目的 探讨 miR-130a-3p 通过靶向糖代谢关键酶 PDK1 对肝癌细胞糖代谢以及增殖迁移的影响, 为肝癌的诊断及治疗提供新的方向。 方法 qRT-PCR 技术检测肝癌的临床组织和细胞中 miR-130a-3p 的表 达, 克隆形成、 CCK-8、 Transwell 和细胞划痕实验检测细胞的增殖和迁移; Western 印迹检测相关蛋白的表 达; 乳酸检测试剂盒, ATP 检测试剂盒和 PDH 活性检测试剂盒分别检测细胞中乳酸的生成、 ATP 的生成和 PDH 的活性; 双荧光素酶报告基因实验验证 miR-130a-3p 与 PDK1 3′UTR 靶向结合。 结果 在肝癌组织和 细胞中 miR-130a-3p 呈低表达, 并与患者肿瘤组织的大小和 TNM 分期有关; 过表达 miR-130a-3p 能够增强 肝癌细胞中 PDH 活性, 抑制乳酸和 ATP 的生成, 从而抑制肝癌细胞的增殖和迁移; miR-130a-3p 可以靶向 调控 PDK1; 抑制 PDK1 的表达, 能够逆转 miR-130a-3p 过表达对细胞增殖和迁移能力的增强, 此外对 PDH 活 性、 乳酸和 ATP 的影响也被逆转。 结论 miR-130a-3p 通过靶向调控 PDK1 影响肝癌细胞糖酵解及恶性进展。     

靶向调控c-SKI的microRNA的筛选及验证

目的筛选和验证靶向调控c-SKI并与纤维化相关的microRNA(miRNA)。方法生物信息学方法预测并结合文献报道,筛选出靶向c-SKI的候选miRNAs,RT-qPCR检测人心肌成纤维细胞(HCFBs)中候选miRNAs和c-SKI的表达,筛选出抑制作用最显著的miRNA;构建c-SKI-3′-UTR野生型(c-SKI-wt)和突变型(c-SKI-mut)载体,分别与miR-155a-5p/miR-17a-5p的模拟物、抑制剂及对照在人胚肾上皮细胞(HEK293T)中共转染,双萤光素酶报告系统检测各组荧光素酶活性;接着,分别将miR-155a/miR-17a-5p mimics和inhibitor转染至人心肌成纤维细胞(HCFBs),Western blot检测各组细胞c-SKI的表达。结果 1)经筛选miR-155a-5p和miR-17a-5p对c-SKI的抑制作用最明显(P<0.01);2)与NC组相比,miR-155a-5p/miR-17a-5p mimics组萤光素酶活性均显著下降(P<0.05),miR-155a-5p/miR-17a-5p inhibitor组萤光素酶活性均明显增强(P<0.05);3)与NC组相比,miR-155a-5p/miR-17a-5p mimics组中c-SKI蛋白表达显著下调,miR-155a-5p/miR-17a-5p inhibitor组中c-SKI的表达显著上调(P<0.01)。结论 miR-155a-5p和miR-17a-5p可分别靶向结合c-SKI的3′-UTR,在HCFBs中负性调控c-SKI的表达。     

微小RNA-199a-5p通过靶向SIRT1促进心肌纤维化相关基因表达

目的:研究微小RNA-199a-5p(miR-199a-5p)对心肌成纤维细胞中纤维化相关基因表达的调控作用及其可能作用的靶基因。方法:原代分离并体外培养成体C57BL/6小鼠心肌成纤维细胞;双萤光素酶报告基因实验检测miR-199a-5p与潜在靶基因沉默信息调节因子1(SIRT1)3’端非翻译区(3’-UTR)的结合作用;实时荧光定量PCR(RT-q PCR)和Western blot法分别检测SIRT1以及纤维化标志物胶原蛋白(Col)1a1、Col3a1和α-平滑肌肌动蛋白(α-SMA)的mRNA和蛋白表达。结果:在血管紧张素Ⅱ(AngⅡ)诱导的小鼠心肌成纤维细胞中,Col1a1、Col3a1和α-SMA的表达增强,miR-199a-5p表达上调。在心肌成纤维细胞中过表达miR-199a-5p可以增强Col1a1、Col3a1和α-SMA的表达。双萤光素酶报告基因实验显示miR-199a-5p与SIRT1 3’-UTR有结合作用。RT-q PCR和Western blot结果证实miR-199a-5p可在转录水平抑制SIRT1表达。过表达miR-199a-5p和沉默SIRT1均能一致性促进心肌成纤维细胞中Col1a1、Col3a1和α-SMA的表达。抑制AngⅡ诱导的小鼠心肌成纤维细胞中NF-κB激活,可显著降低miR-199a-5p表达。结论:SIRT1是miR-199a-5p的作用靶基因,并介导miR-199a-5p促进纤维化标志物Col1a1、Col3a1和α-SMA的表达。     

LncRNA TMPO-AS1 up-regulates the expression of HIF-1α and promotes the malignant phenotypes of retinoblastoma cells via sponging miR-199a-5p

BackgroundLong non-coding RNA (lncRNA) TMPO antisense RNA 1 (TMPO-AS1) is reported to be oncogenic in prostate cancer and lung cancer. This study aims to investigate the expression and biological function of it in retinoblastoma (RB), and explore its regulatory role for miR-199a-5p and hypoxia-inducible factor-1α (HIF-1α).MethodsPaired RB samples were collected, and the expression levels of TMPO-AS1, miR-199a-5p and HIF-1α were examined by quantitative real-time polymerase chain reaction (qRT-PCR); TMPO-AS1 overexpressing plasmids and TMPO-AS1 shRNA were transfected into HXO-RB44 and SO-Rb50 cell lines respectively, and then proliferation, migration and invasion of RB cells were detected by CCK-8 assay and Transwell method. qRT-PCR and western blot were used to analyze the regulatory function of TMPO-AS1 on miR-199a-5p and HIF-1α; luciferase reporter gene assay was used to determine the regulatory relationship between miR-199a-5p and TMPO-AS1.ResultsTMPO-AS1 was significantly up-regulated in cancerous tissues of RB samples (relatively expression: 2.97 vs 3.93, p < 0.001), negatively correlated with miR-199a-5p (r=-0.4813, p < 0.01). There was one binding site on TMPO-AS1 for miR-199a-5p. After transfection of TMPO-AS1 shRNAs into RB cells, the proliferation, migration and invasion of cancer cells was significantly inhibited, while TMPO-AS1 had opposite effects; TMPO-AS1 was also demonstrated to regulate the expression of HIF-1α on both mRNA and protein levels via negatively regulating miR-199a-5p.ConclusionTMPO-AS1 is abnormally up-regulated in RB tissues, and it can modulate the proliferation and migration of RB cells. It has the potential to be the “ceRNA” to regulate HIF-1α expression by sponging miR-199a-5p.     

MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease

MicroRNA (miR)-219a-5p has been implicated in the development of numerous progression of carcinoma and autoimmune diseases. However, whether miR-219a-5p is involved in the pathogenesis of inflammatory bowel disease (IBD) remains elusive. In this study, we demonstrated that miR-219a-5p expression was significantly decreased in the inflamed intestinal mucosa and peripheral blood (PB)-CD4⁺ T cells from patients with IBD. Proinflammatory cytokines (e.g., IL-6, IL-12, IL-23 and TNF-α) inhibited miR-219a-5p expression in CD4⁺ T cells in vitro. Lentivirus-mediated miR-219a-5p downregulation facilitated Th1/Th17 cell differentiation, whereas miR-219a-5p overexpression exerted an opposite effect. Luciferase assays confirmed that ETS variant 5 (ETV5) was a functional target of miR-219a-5p and ETV5 expression was significantly increased in the inflamed intestinal mucosa and PB-CD4⁺ T cells from IBD patients. ETV5 overexpression enhanced Th1/Th17 immune response through upregulating the phosphorylation of STAT3 and STAT4. Importantly, supplementation of miR-219a-5p ameliorated TNBS-induced intestinal mucosal inflammation, characterized by decreased IFN-γ⁺ CD4⁺ T cells and IL-17A⁺ CD4⁺ T cells infiltration in the colonic lamina propria. Our data thus reveal a novel mechanism whereby miR-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses. miR-219a-5p might be a target for the treatment of IBD.     

Mechanism underlying the regulation of lncRNA ACTA2-AS1 on CXCL2 by absorbing miRNA-532-5p as ceRNA in the development of ovarian cancer

Objective: To explore the mechanism underlying the regulation of long non-coding RNA (LncRNA) ACTA2-AS1 on CXCL2 as a ceRNA of miR-532-5p in the progression of ovarian cancer (OC). Methods: A qRT-PCR assay was carried out for analyzing the expression changes of ACTA2-AS1, miR-532-5p, as well as CXCL2 in OC tissues and corresponding healthy paracancerous tissues HOSEpiC (human ovarian epithelial cells), and OC cells. OC cells were grouped and transfected, and the fluorescent in situ hybridization was adopted for evaluating ACTA2-AS1 in the cells. Additionally, a dual luciferase reporter (DLR) assay was carried out for verifying the correlation of ACTA2-AS1 with miR-532-5p and of miR-532-5p with CXCL2. Cells were transfected with si-ACTA2-AS1, miR-532-5p, or CXCL2 overexpression plasmids, and then the cell proliferation, invasion, and apoptosis were determined using MTT, Transwell, and flow cytometry assays, respectively. Results: Compared with paracancerous tissues and HOSEpiC cells, OC tissues and cells showed increased ACTA2-AS1 and CXCL2 expression and decreased miR-532-5p expression (all P<0.05). ACTA2-AS1 acted as ceRNA in OC by negatively regulating miR-532-5p. Additionally, upregulating ACTA2-AS1 intensified the proliferation and invasion of cancer cells and suppressed their apoptosis (all P<0.05), and inhibition of it resulted in opposite results. In contrast, overexpressing miR-532-5p suppressed the proliferation, invasion, and clone formation of the cells and promoted their apoptosis (all P<0.05). The effect of ACTA2-AS1 on OC cells can be partially reversed by overexpressing miR-532-5p. Moreover, CXCL2, positively correlated with ACTA2-AS1 in expression (P<0.0001, r=0.7385), was the target of miR-532-5p, and its overexpression could partially offset the influence of miR-532-5p on OC cells. Conclusion: LncRNA ACTA2-AS1 can act as a tumor promoter in OC by absorbing miR-532-5p as ceRNA and regulating CXCL2, and ACTA2-AS1 inhibitor is expected to play a role in targeted therapy of OC.     

miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2

Oral squamous cell carcinomas (OSCCs) are one of the most ubiquitous malignancies the world over, and are accompanied by a high mortality. microRNAs (miRNAs) have increasingly garnered attention with regards to the roles they play in initiation and progression of various kinds of cancers, including OSCC. It has been reported, that miR-23a-3p promotes the development of tumors for prostate cancer, gastric cancer and gliomas. The functions of miR-23a-3p in OSCC however, remain unclear. In this study, fibroblast growth factor 2 (FGF2) is revealed as a direct target of miR-23a-3p, based on luciferase assays and immunoblotting. The expression of miR-23a-3p and FGF2 were found to be significantly downregulated and upregulated in OSCC tissues respectively. This indicates a reverse correlation between miR-23a-3p and FGF2 levels. Using in vitro approaches we ascertained that miR-23a-3p might contribute to the inhibition of growth and inhibition through increasing apoptosis in OSCC cells; while an inhibitor of miR-23a-3p could reverse this effect. Examination of a clinical cohort of OSCC patients suggested that reduced expression of miR-23a-3p is correlated with more advanced cancerous stage and poorer differentiation of OSCC cell. Additionally, a survival analysis and the Cox-hazard regression model showed that higher levels of miR-23a-3p can be used reliably for prognosis of OSCC patients. This study indicates that miR-23a-3p might suppress tumor proliferation, invasion and promote apoptosis of OSCC by targeting FGF2. miR-23a-3p has the potential to be used as prognostic indicator, and could be exploited as a therapeutic reagent for OSCC in the future.     

miR-30a抑制人骨肉瘤细胞143B的迁移、侵袭和活力

目的探讨miR-30a对人骨肉瘤细胞143B侵袭、迁移和细胞活力的影响。方法过表达或抑制miR-30a分别处理人骨肉瘤细胞143B。划痕实验观察细胞划痕愈合能力;Transwell实验检测143B细胞迁移和侵袭能力;MTT实验检测细胞活力;定量PCR实验确认过表达miR-30a腺病毒有效性并且检测RUNX2 mRNA表达;Western blot检测细胞中RUNX2总蛋白表达。结果过表达miR-30a抑制了骨肉瘤细胞143B迁移和侵袭(P0.05),在72 h时,miR-30a明显抑制细胞活力(P0.01);抑制miR-30a的内源性表达后,143B细胞的迁移和侵袭能力增加(P0.05),细胞活力也表现出上升水平(P0.01);同时过表达miR-30a可以抑制RUNX2的蛋白表达,抑制内源性miR-30a后RUNX2蛋白水平表达增加(P0.05)。荧光素酶活性检测,miR-30a可以靶向于RUNX2(P0.01)。结论 miR-30a抑制骨肉瘤细胞143B的迁移、侵袭和活力,其作用可以能是通过抑制RUNX2的表达来实现。     

miR-654-3p靶向GMFB抑制骨肉瘤细胞增殖的作用及机制研究

目的 探究miR-654-3p对骨肉瘤细胞增殖的影响，预测其靶基因并评估靶基因对骨肉瘤患者生存预后的干预情况。方法 选择GEO数据库中GSE70367数据集进行差异分析，筛选骨肉瘤细胞中异常表达的miRNA，通过RT-qPCR检测miR-654-3p在骨肉瘤细胞系143B、MG-63、SAOS2和HOS中的表达情况。通过TargetScan和miRmap数据库预测miR-654-3p的靶基因，采用双荧光素酶报告基因实验验证miR-654-3p与GMFB基因的结合。用CCK8实验和CFU实验分析miR-654-3p和GMFB对骨肉瘤细胞MG-63和HOS增殖的影响。下载TCGA数据库中肉瘤患者的GMFB表达数据和临床信息，通过R软件包绘制GMFB对生存预后影响的KM曲线以及预测肉瘤患者1年、3年和5年生存率的列线图。结果 与人正常成骨细胞hFOB1.19相比，骨肉瘤细胞系143B、MG-63、SAOS2和HOS中miR-654-3p的表达均明显降低（P＜0.05）。miR-654-3p与GMFB基因结合，并负调控GMFB的表达。miR-654-3p模拟物在体外明显抑制骨肉瘤细胞的增殖，而GMFB转染能够逆转抑制作用（P＜0.05）。GMFB高表达的骨肉瘤患者的总体生存率明显低于低表达患者（P＜0.05），且通过列线图能够预测患者的1年、3年和5年生存率。结论 miR-654-3p通过靶向负调控GMFB基因表达，抑制骨肉瘤细胞的增殖，且GMFB高表达与骨肉瘤患者的预后呈负相关。